✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

Aarti Pharmalabs Ltd.

AARTIPHARM

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹7,655 Cr.
P/E
28.73

Aarti Pharmalabs Ltd.

  • Aarti Pharmalabs
  • Shilpa Medicare
  • Supriya Lifescience

FAQs on Aarti Pharmalabs Ltd. Shareprice

Aarti Pharmalabs has given better returns compared to its competitors.
Aarti Pharmalabs has grown at ~48.04% over the last 2yrs while peers have grown at a median rate of 41.93%

Yes, Aarti Pharmalabs is expensive.
Latest PE of Aarti Pharmalabs is 29.17, while 3 year average PE is 24.26.
Also latest EV/EBITDA of Aarti Pharmalabs is 17.62 while 3yr average is 15.84.

View FAQ's On Business

Growth Table

  • Aarti Pharmalabs Ltd.
  • Shilpa Medicare
  • Supriya Lifescience

Balance Sheet

  • Aarti Pharmalabs Ltd.
  • Shilpa Medicare
  • Supriya Lifescience

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Aarti Pharmalabs Ltd.
  • Shilpa Medicare
  • Supriya Lifescience

Cash Flow

  • Aarti Pharmalabs Ltd.
  • Shilpa Medicare
  • Supriya Lifescience

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Aarti Pharmalabs Ltd.
  • Shilpa Medicare
  • Supriya Lifescience

Quarterly Results

  • Aarti Pharmalabs Ltd.
  • Shilpa Medicare
  • Supriya Lifescience

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Aarti Pharmalabs Ltd. Financials

Balance sheet of Aarti Pharmalabs is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Aarti Pharmalabs is increasing.
Latest net debt of Aarti Pharmalabs is ₹379 Crs as of Mar-25.
This is greater than Mar-24 when it was ₹216 Crs.

The profit is oscillating.
The profit of Aarti Pharmalabs is ₹268 Crs for TTM, ₹272 Crs for Mar 2025 and ₹217 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Aarti Pharmalabs latest dividend payout ratio is 16.64% and 3yr average dividend payout ratio is 12.85%

Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Capital Work in Progress

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech